Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jun 3;26(6):euae146.
doi: 10.1093/europace/euae146.

Health-related quality of life and healthcare costs of symptoms and cardiovascular disease events in patients with atrial fibrillation: a longitudinal analysis of 27 countries from the EURObservational Research Programme on Atrial Fibrillation general long-term registry

Marjan Walli-Attaei  1 , Mathew Little  1 , Ramon Luengo-Fernandez  2 , Alastair Gray  1 , Aleksandra Torbica  3 , Aldo P Maggioni  4 , Firoozeh Bairami  5 , Radu Huculeci  5 , Victor Aboyans  6 , Adam D Timmis  7 , Panos Vardas  8 , Jose Leal  1
Affiliations
Observational Study

Health-related quality of life and healthcare costs of symptoms and cardiovascular disease events in patients with atrial fibrillation: a longitudinal analysis of 27 countries from the EURObservational Research Programme on Atrial Fibrillation general long-term registry

Marjan Walli-Attaei et al. Europace. .

Abstract

Aims: We examine the effects of symptoms and cardiovascular disease (CVD) events on health-related quality of life (HRQOL) and healthcare costs in a European population with atrial fibrillation (AF).

Methods and results: In the EURObservational Research Programme on AF long-term general registry, AF patients from 250 centres in 27 European countries were enrolled and followed for 2 years. We used fixed effects models to estimate the association of symptoms and CVD events on HRQOL and annual healthcare costs. We found significant decrements in HRQOL in AF patients in whom ST-segment elevation myocardial infarction (STEMI) [-0.075 (95% confidence interval -0.144, -0.006)], angina or non-ST-elevation myocardial infarction (NSTEMI) [-0.037 (-0.071, -0.003)], new-onset/worsening heart failure [-0.064 (-0.088, -0.039)], bleeding events [-0.031 (-0.059, -0.003)], thromboembolic events [-0.071 (-0.115, -0.027)], mild symptoms [0.037 (-0.048, -0.026)], or severe/disabling symptoms [-0.090 (-0.108, -0.072)] occurred during the follow-up. During follow-up, annual healthcare costs were associated with an increase of €11 718 (€8497, €14 939) in patients with STEMI, €5823 (€4757, €6889) in patients with angina/NSTEMI, €3689 (€3219, €4158) in patients with new-onset or worsening heart failure, €3792 (€3315, €4270) in patients with bleeding events, and €3182 (€2483, €3881) in patients with thromboembolic events, compared with AF patients without these events. Healthcare costs were primarily driven by inpatient costs. There were no significant differences in HRQOL or healthcare resource use between EU regions or by sex.

Conclusion: Symptoms and CVD events are associated with a high burden on AF patients and healthcare systems throughout Europe.

Keywords: Atrial fibrillation; Health-related quality of life; Healthcare costs.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J.L., A.G., and R.L.F. report research grants from ESC. A.D.T. has stock in two start-up companies, receiving no income from these investments. A.T. has a consultancy agreement with ESC. A.P.M. reports payments from Astra Zeneca, Novartis, Sanofi, and Bayer for participation in study committees in areas outside the present work. P.V. reports consulting fees from Servier International, Hygeia Hospital Group, and ESC. M.W.A., R.H., and M.L. report no disclosures.

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
Marginal effects (95% CI) of symptoms and CVD events on HRQOL and healthcare costs (€) of women relative to men. Symptoms measured using EHRA classification score. FE models with interaction terms for symptoms and CVD events with biological sex. Models adjusted for unknown time-invariant confounders and for the following observed time-variant confounders: clinical type of AF, age, medications used before each visit, and time period. Men are the reference category. AF, atrial fibrillation; CI, confidence interval; CVD, cardiovascular disease; EHRA, European Heart Rhythm Association; FE, fixed effects; HRQOL, health-related quality of life; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
Figure 2
Figure 2
Marginal effects (95% CI) of symptoms and CVD events on HRQOL and healthcare costs (€) by region. Acute coronary syndromes includes Angina/NSTEMI and STEMI (STEMI was not estimated in Northern EU due to few events). Symptoms measured using EHRA classification score. FE models with interaction terms symptoms and CVD events with region. Models adjusted for unknown time-invariant confounders and for the following observed time-variant confounders: clinical type of AF, age, medications used before each visit, and time period. Western EU is the reference category. Northern EU countries: Denmark, Estonia, Latvia, Norway, and the UK; Western EU countries: Belgium, France, Germany, the Netherlands, and Switzerland; Eastern EU countries: Bulgaria, Czech Republic, Georgia, Kazakhstan, Kyrgyzstan, Poland, Romania, and Russia; Southern EU countries: Albania, North Macedonia, Italy, Malta, Montenegro, Portugal, Serbia, Spain, and Turkey. AF, atrial fibrillation; CI, confidence interval; CVD, cardiovascular disease; EHRA, European Heart Rhythm Association; FE, fixed effects; HRQOL, health-related quality of life; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
See this image and copyright information in PMC

References

    1. Li H, Song X, Liang Y, Bai X, Liu-Huo W-S, Tang C et al. Global, regional, and national burden of disease study of atrial fibrillation/flutter, 1990–2019: results from a global burden of disease study, 2019. BMC Public Health 2022;22:2015. - PMC - PubMed
    1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983–8. - PubMed
    1. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 2015;36:3250–7. - PMC - PubMed
    1. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res 2017;120:1501–17. - PMC - PubMed
    1. Sgreccia D, Manicardi M, Malavasi VL, Vitolo M, Valenti AC, Proietti M et al. Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic review and meta-analysis of 81,462 patients. J Clin Med 2021;10:3979. - PMC - PubMed

Publication types

MeSH terms